



EVITRADE Health Systems Corporation

EVITRADE Health Announces Non-Binding LOI with Cantech Molecular Research Inc.

VANCOUVER, BC, Tuesday, December 5, 2017 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: AXHLF) (the “Company” or “EVITRADE”) announces the signing of a non-binding letter of intent with Cantech Molecular Research Inc. Cantech Molecular Research Inc. is a high level medical technology service company that is unique as it brings a range of specialized services including genetic sequencing and bioformatics, full biological and environmental analysis capabilities, a full imaging division including confocal laser scanning imaging system services, and has the latest in GC-MS (Gas Chromatography and Mass Spectrometry) technology available as product and service offerings in its two current primary divisions:

- 1) Advanced tissue culture services for the medical cannabis industry, both for medical marijuana and industrial hemp. Cantech’s senior staff has over 20 years of hands on experience working with plant biotechnology, physiology, advanced tissue culture, plant breeding and development. Their knowledge has led them to work alongside many multinational corporations domestically and internationally at both a breeding and molecular level. This experience has given them the ability to produce and maintain mass quantities of exclusive cultivars that are all genetically identical. These identical seedlings will have the option to be pre-selected with desired traits, allowing them to develop new varieties of exact cultivars with very targeted THC/CBD combinations.
- 2) Cantech’s breeding programs will contain patentable cultivars that have been certified disease and pesticide free. Their services can eliminate previously unavoidable costs associated with the production of elite plants within the agricultural market. Cantech may also offer the option of full genetic mapping services at a genetic level for a wide variety of different markets within the medical cannabis and hemp industries.

“The proposed acquisition of Cantech Molecular Research Inc. should serve as an excellent addition to our current offerings at Evitrade. We see fantastic growth opportunities, and look forward to the potential expansion into new markets with Cantech Molecular Research Inc.” said Sydney Au, CEO.

Management looks forward to providing further details as developments on this Letter of Intent as they become available.

Contact:

Ron Ozols, Director, EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)



**EVITRADE
Health
Systems
Corporation**

EVITRADE Health Systems Corporation

Email: ceo@auxellence.com or info@auxellence.com

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

About EVITRADE Health Systems Corporation (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online health technologies and services for resolving common health problems.

Disclaimers – Forward Looking Statements

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on www.sedar.com, and <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.